XMD17-109
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
XMD17-109是一种新的ERK5抑制剂，在HeLa细胞中的IC50值为0.09 ± 0.03 μM，在体外酶试验中的IC50值为0.162 ± 0.006 μM。
XMD17-109具有抑制细胞中ERK5自磷酸化的能力。[1]
小鼠静脉注射和口服XMD17-109的药代动力学如下：T1/2（半衰期）为8.2 h。血浆清除率为8.64 mL/min/Kg（静脉注射数据），口服的AUC（曲线下面积）为15745 h*ng/mL，口服生物利用度为90%。
参考文献：
1. Deng, X., et al., Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. European Journal of Medicinal Chemistry, 2013. 70: p. 758-767.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 638.8 |
| Cas No. | 1435488-37-1 |
| Formula | C36H46N8O3 |
| Synonyms | XMD17 109 |
| Solubility | ≥31.95 mg/mL in DMSO; insoluble in H2O; ≥86.6 mg/mL in EtOH |
| SDF | Download SDF |
| Canonical SMILES | CN1CCN(C2CCN(C(C3=CC(OCC)=C(NC4=NC=C5C(N(C6CCCC6)C(C=CC=C7)=C7C(N5C)=O)=N4)C=C3)=O)CC2)CC1 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Description | XMD17-109是一种新的ERK-5特异性抑制剂，在HEK293细胞中EC50值为4.2 μM。 | |||||
| 靶点 | ERK-5 | |||||
| IC50 | 4.2±0.69 μM(EC50, in HEK 293 cells) | |||||
质量控制和MSDS
- 批次:
化学结构
相关生物数据
